Page last updated: 2024-12-11
daurichromenic acid
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
daurichromenic acid: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 6475854 |
| CHEMBL ID | 1171643 |
| MeSH ID | M0472575 |
Synonyms (13)
| Synonym |
|---|
| (+)-daurichromenic acid |
| (2s)-2-[(3e)-4,8-dimethylnona-3,7-dienyl]-5-hydroxy-2,7-dimethyl-chromene-6-carboxylic acid |
| (s)-2-((e)-4,8-dimethyl-nona-3,7-dienyl)-5-hydroxy-2,7-dimethyl-2h-1-benzopyran-6-carboxylic acid |
| daurichromenic acid |
| (2s)-2-[(3e)-4,8-dimethylnona-3,7-dienyl]-5-hydroxy-2,7-dimethylchromene-6-carboxylic acid |
| CHEMBL1171643 |
| 82003-90-5 |
| FS-9068 |
| (s,e)-2-(4,8-dimethylnona-3,7-dien-1-yl)-5-hydroxy-2,7-dimethyl-2h-chromene-6-carboxylic acid |
| bdbm50537945 |
| AKOS040761576 |
| CS-0024072 |
| HY-N3692 |
Research Excerpts
Overview
Daurichromenic acid is a meroterpenoid with various pharmacological activities. It is biosynthesized from grifolic acid in Rhododendron dauricum.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Daurichromenic acid is a meroterpenoid with various pharmacological activities that is biosynthesized from grifolic acid in Rhododendron dauricum. " | ( Combinatorial Biosynthesis of (+)-Daurichromenic Acid and Its Halogenated Analogue. Abe, I; Awakawa, T; Iijima, M; Kurosaki, F; Li, C; Okada, M; Saito, K; Taura, F; Wang, D; Wong, CP, 2017) | 2.18 |
| "Daurichromenic acid (DCA) is a meroterpenoid with anti-HIV activities that is isolated from Rhododendron dauricum L. " | ( Daurichromenic acid and grifolic acid: Phytotoxic meroterpenoids that induce cell death in cell culture of their producer Rhododendron dauricum. Iijima, M; Kurosaki, F; Taura, F, 2018) | 3.37 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (1)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Amyloid-beta precursor protein | Homo sapiens (human) | IC50 (µMol) | 24.7000 | 0.0005 | 3.8895 | 10.0000 | AID1646857 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (79)
Molecular Functions (13)
Ceullar Components (41)
Bioassays (3)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1646857 | Inhibition of human amyloid beta (1 to 40) aggregation after 24 hrs by ThT fluorescence assay | 2020 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2 | Isolation of three new meroterpenoids and seven known compounds from Albatrellus yasudae and their Aβ-aggregation inhibitory activity. |
| AID492523 | Therapeutic index, ratio of IC50 for human H9 cells to EC50 for HIV 3B | 2010 | Journal of natural products, Mar-26, Volume: 73, Issue:3 | Discovery and development of natural product-derived chemotherapeutic agents based on a medicinal chemistry approach. |
| AID492522 | Antiviral activity against HIV1 3B infected in H9 cells assessed as inhibition of viral replication by p24 antigen ELISA | 2010 | Journal of natural products, Mar-26, Volume: 73, Issue:3 | Discovery and development of natural product-derived chemotherapeutic agents based on a medicinal chemistry approach. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (12)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 7 (58.33) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 21.47
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (21.47) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (8.33%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 11 (91.67%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||